Trastuzumab--mechanism of action and use in clinical practice
about
Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodiesThe HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in TherapyContribution of CXCL12 secretion to invasion of breast cancer cells.Lapatinib for metastatic breast cancer overexpressing HER2Lost in Translation (LiT): IUPHAR Review 6Multiple functions of sushi domain containing 2 (SUSD2) in breast tumorigenesisAnaplastic lymphoma kinase: signalling in development and diseaseCharacterisation of HER heterodimers in breast cancer using in situ proximity ligation assayTargeting cellular metabolism to improve cancer therapeuticsCritical appraisal of trastuzumab in treatment of advanced stomach cancerMimotope vaccination--from allergy to cancerThe use of lentinan for treating gastric cancerIL-25 causes apoptosis of IL-25R-expressing breast cancer cells without toxicity to nonmalignant cellsHigh risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smallerLatent bone metastasis in breast cancer tied to Src-dependent survival signalsA phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neuInteraction of TFAP2C with the estrogen receptor-alpha promoter is controlled by chromatin structureTumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast CancerHER2 testing in gastric cancer: An updateMechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome ItAutophagy and Apoptotic Crosstalk: Mechanism of Therapeutic Resistance in HER2-Positive Breast CancerTargeted therapies with companion diagnostics in the management of breast cancer: current perspectivesPharmacologic resistance in colorectal cancer: a reviewMechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancerPersonalized medicine in gastric cancer: Where are we and where are we going?Targeted Therapies in HER2-Positive Breast Cancer - a Systematic ReviewTargeting RTK Signaling Pathways in CancerHow can clinical research help our understanding of trastuzumab-related cardiotoxicity?Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature reviewDual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancerPatterns of Chromosomal Aberrations in Solid TumorsChallenges in Antibody Development against Tn and Sialyl-Tn AntigensMolecular classification of gastric cancer: Towards a pathway-driven targeted therapyMaterials based tumor immunotherapy vaccinesNucleic Acid Aptamers: An Emerging Tool for Biotechnology and Biomedical SensingSite-specific functionalization of proteins and their applications to therapeutic antibodiesApproaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cellsNewer therapies for the treatment of metastatic breast cancer: a clinical updateRole of trastuzumab emtansine in the treatment of HER2-positive breast cancerNovel immunotherapeutic strategies of gastric cancer treatment
P2860
Q21131216-9CE04F05-9F45-4D21-834E-6734558C8AAEQ21284978-7C8889A4-8AA2-49CC-8F98-88159E32D746Q22000754-7A4F3175-EEF7-4EF2-887F-C412677BAF1AQ24203605-861B3915-9A37-40AF-898E-2C05F80BBF05Q24289150-A7905329-AA8E-438E-A2CE-BF381FC09AB4Q24302420-731E3A6D-5D21-4235-A0F4-D7984A922103Q24312329-A6737E58-D652-4710-9C3D-35A47E162476Q24337937-15B93944-1EBA-4A61-BEAD-0D38F72766E9Q24596727-756884E9-12DA-48CC-AE86-627BD1ADD477Q24604411-F31349B1-D7C0-4A89-984A-944CFC8831E7Q24608624-17AD5A1C-CDBC-400A-8E17-3A1E2411471AQ24619416-E5B23AFF-64A1-4682-AB05-8455AD8D0256Q24634798-4202AD9F-81A6-49D3-85A8-3A5D12BD540FQ24641848-F52B00E2-EB2A-4C9B-A9C6-F9BFE47DD8D6Q24648828-6296A101-9C77-4EF1-A3AC-FBE607D97B3DQ24649530-2AF9252C-45CB-423A-949A-9449823DD25BQ24657263-025FF0D7-D78C-4686-8D03-D9F51AEA1D30Q26745446-A66B1912-8B60-479E-A710-249F90622414Q26746253-A456C964-49EA-4CBE-B3BE-1C363DEBBC06Q26752780-9B98F697-8470-4514-8724-33BDEAF5D6BCQ26753162-B547FBFA-D526-4FDC-BE59-396B8B664095Q26768119-EDBFB513-6B88-4F9B-A7C2-85FCCD0CB7A6Q26769850-009EB31F-17A3-4D58-8342-6FFAA50E511BQ26772969-8A4CBC5F-FEF9-485B-B601-B0766954F752Q26774521-1C3B777E-C1BD-40D1-97B1-FD7DB59E74B0Q26777733-92F868FE-060E-4A51-B797-59097D99FEB4Q26781278-7C19C63C-804B-4334-962B-6B7297FE94C2Q26783121-673B7FCC-DBD5-42B7-9049-C01DE5790852Q26783596-316F164D-C6FA-40AB-A1E3-2BFDCBAE3F66Q26785612-FBF7A78E-5A5E-462B-9184-179447206D4AQ26786127-71E0E6EE-8818-43CC-BCEC-70D599D5F45AQ26798183-ECAC18FF-DB63-4757-8583-53091FA67CB0Q26798420-E461F997-B566-4D43-8E74-F34107384029Q26824135-A6922BD9-2BBA-4F06-B2D3-C40F35EFCF52Q26825644-99EB027B-683D-4139-B95B-98D42B87FB97Q26830699-66C94A83-0285-4C7E-AF9B-03459110F28DQ26852287-E4ABF49D-4A2E-4FF4-ADB8-E55EAFBACE0DQ26865260-DEEE8A5D-C675-42D8-9398-8641B927F81EQ27003258-FB94F5DF-0461-46C5-A47F-43D5AAC47682Q27011232-DA3541E9-6C28-4906-9AA8-E8A79FF28549
P2860
Trastuzumab--mechanism of action and use in clinical practice
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Trastuzumab--mechanism of action and use in clinical practice
@ast
Trastuzumab--mechanism of action and use in clinical practice
@en
type
label
Trastuzumab--mechanism of action and use in clinical practice
@ast
Trastuzumab--mechanism of action and use in clinical practice
@en
prefLabel
Trastuzumab--mechanism of action and use in clinical practice
@ast
Trastuzumab--mechanism of action and use in clinical practice
@en
P3181
P356
P1476
Trastuzumab--mechanism of action and use in clinical practice
@en
P2093
P3181
P356
10.1056/NEJMRA043186
P407
P577
2007-07-05T00:00:00Z